SCHEMBL3016085

SCHEMBL3016085

COc1cc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(F)c(Cl)c4)CC3)n2)cc(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.39
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
RECQL P46063 1/20 0.39
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
F2RL3 Q96RI0 8/20 0.35
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
DRD2 P14416 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
KCNH2 Q12809 1/20 0.34
F2 P00734 1/20 0.34
TP53 P04637 2/20 0.33
S1PR1 P21453 1/20 0.33
S1PR3 Q99500 1/20 0.33
LMNA P02545 2/20 0.33
GPR6 P46095 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013116 0.93 MAPT (0.39) MAPTHSD17B10USP2RECQLHCRTR1
SCHEMBL3013270 0.93 MAPT (0.44) MAPTHSD17B10USP2RECQLTP53
SCHEMBL3014057 0.92 MAPT (0.37) MAPTHSD17B10USP2RECQLF2RL3
SCHEMBL3009031 0.90 PSEN1 (0.36) MAPTHSD17B10USP2RECQLF2RL3
SCHEMBL3008157 0.90 HTR2A (0.37) MAPTRAB9ASMN1; SMN2DRD2HTR2A
SCHEMBL3011211 0.90 ALDH1A1 (0.36) MAPTHSD17B10USP2RECQLF2RL3
SCHEMBL3009705 0.89 DNM1L (0.35) MAPTSMN1; SMN2DRD2HTR2AHTR2C
SCHEMBL3008184 0.89 HTR2A (0.38) MAPTHSD17B10USP2RECQLRAB9A
SCHEMBL3021608 0.89 MAPT (0.45) MAPTHSD17B10USP2RECQLF2RL3
SCHEMBL3009255 0.89 HTR2A (0.37) MAPTRAB9ASMN1; SMN2DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.